Preventing Hand-Foot Syndrome in Patients With Cancer: A Systematic Review and Network Meta-Analysis - PubMed
4 hours ago
- #chemotherapy
- #meta-analysis
- #hand-foot syndrome
- Hand-foot syndrome (HFS) is a common dose-limiting side effect of chemotherapy, especially with capecitabine, impacting patient quality of life and treatment efficacy.
- A systematic review and network meta-analysis evaluated pharmacologic interventions for preventing HFS, analyzing 19 RCTs with 2192 patients.
- Topical silymarin, diclofenac, 400-mg pyridoxine, and celecoxib significantly reduced the incidence of grade 2 or higher HFS compared to placebo.
- Diclofenac and celecoxib also reduced the overall incidence of HFS, while mapisal increased the risk.
- Silymarin and diclofenac ranked highest in effectiveness, with diclofenac having the best overall supporting evidence.
- The study highlights the need for larger randomized trials to confirm the efficacy of silymarin.